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MaOBJECTIVES This study evaluated the tolerability and feasibility of titration of 2 distinctly acting beta-blockers (BB) in
elderly heart failure patients with preserved (HFpEF) and reduced (HFrEF) left ventricular ejection fraction.
BACKGROUND Broad evidence supports the use of BB in HFrEF, whereas the evidence for beta blockade in
HFpEF is uncertain.
METHODS In the CIBIS-ELD (Cardiac Insufﬁciency Bisoprolol Study in Elderly) trial, patients >65 years of age with
HFrEF (n ¼ 626) or HFpEF (n ¼ 250) were randomized to bisoprolol or carvedilol. Both BB were up-titrated to the target
or maximum tolerated dose. Follow-up was performed after 12 weeks. HFrEF and HFpEF patients were compared
regarding tolerability and clinical effects (heart rate, blood pressure, systolic and diastolic functions, New York Heart
Association functional class, 6-minute-walk distance, quality of life, and N-terminal pro–B-type natriuretic peptide).
RESULTS For both of the BBs, tolerability and daily dose at 12 weeks were similar. HFpEF patients demonstrated higher
rates of dose escalation delays and treatment-related side effects. Similar HR reductions were observed in both groups
(HFpEF: 6.6 beats/min; HFrEF: 6.9 beats/min, p ¼ NS), whereas greater improvement in NYHA functional class was
observed in HFrEF (HFpEF: 23% vs. HFrEF: 34%, p < 0.001). Mean E/e0 and left atrial volume index did not change in
either group, although E/A increased in HFpEF.
CONCLUSIONS BB tolerability was comparable between HFrEF and HFpEF. Relevant reductions of HR and blood
pressure occurred in both groups. However, only HFrEF patients experienced considerable improvements in clinical
parameters and left ventricular function. Interestingly, beta-blockade had no effect on established and prognostic
markers of diastolic function in either group. Long-term studies using modern diagnostic criteria for HFpEF are urgently
needed to establish whether BB therapy exerts signiﬁcant clinical beneﬁt in HFpEF. (Comparison of Bisoprolol and
Carvedilol in Elderly Heart Failure [HF] Patients: A Randomised, Double-Blind Multicentre Study [CIBIS-ELD];
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141AB BR E V I A T I O N S
AND ACRONYM S
BB = beta-blockers
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
HR = heart rate
LAVI = left atrial volume index
LVEF = left ventricular
ejection fraction
LVMI = left ventricular mass
index
QoL = quality of lifeC hronic heart failure (HF) continues to be amajor health problem in the community (1).Nearly one-half of HF patients have pre-
served left ventricular ejection fraction (HFpEF) (2),
and the prevalence of HFpEF patients is increasing
(3). Recent data suggest that mortality and readmis-
sion rates in HFpEF are higher than described and
that the overall prognosis is comparable to HFrEF
(2,3). Furthermore, although survival rates of HFrEF
patients improved over the past decades, mortality
remains unchanged in HFpEF patients (3). The
diverging mortality trend reﬂects a lack of treatments
with proven survival beneﬁt for HFpEF, resulting
partially, from the scarcity of large clinical trials in
this condition (4).SEE PAGE 150Robust evidence supports the use of beta-blockers
(BB) in HFrEF, although their use in HFpEF remains
controversial (5). BBs could theoretically be useful
and recommended by guidelines to control HR in
HFpEF (e.g., by lowering blood pressure [BP] and/or
afterload, reducing left ventricular hypertrophy,
lengthening diastolic ﬁlling time, and reducing high
ventricular rates, which are poorly tolerated in this
condition) (6). They also reduce the risk of ventricular
arrhythmias, which are one of the most common
modes of death in HFpEF (7). Registry data, 1 small
randomized, controlled trial, and the large SENIOR
study, have suggested a prognostic beneﬁt due to
beta-blockade in HFpEF (8–10). SENIOR study, how-
ever, using only a left ventricular ejection fraction
(LVEF) cutoff value of >35% for the deﬁnition of
HFpEF, has been criticized (9). On the other hand, the
OPTIMIZE-HF (Organized Program to Initiate Life-
saving Treatment in Hospitalized Patients with Heart
Failure) registry showed that the use of BBs in HFpEF
patients was be related to poor outcomes (11), and
another small observational study suggested that BB
therapy may lead to a higher risk of rehospitalization
in women with HFpEF (12).
However, little is still known about the tolerability
of BBs in HFpEF. Although the overall tolerability of
nebivolol was found to be similar for both HFrEF and
HFpEF in the SENIOR study, prescription of BBs in
both conditions remains low despite evidence of their
prognostic beneﬁt in HFrEF (13). The main results
from the CIBIS-ELD (Cardiac Insufﬁciency Bisoprolol
Study in Elderly) trial suggest that there is no differ-
ence in achieved doses and tolerability to target doses
between bisoprolol and carvedilol in elderly HF pa-
tients (14). Although BBs are currently indicated to
treat comorbidities associated with HFpEF, there are
no recommendations of how to initiate BB treatmentin HFpEF (15). Also according to the primary
objective of the CIBIS-ELD trial, which
addressed the superiority of bisoprolol versus
carvedilol, in this pre-speciﬁed analysis, we
therefore compared the tolerability and clin-
ical effectiveness of these 2 differentially
acting BBs on the burden of symptoms,
functional capacity, and echocardiographic
assessment of systolic and diastolic myocar-
dial function in elderly HFrEF and HFpEF
patients (16).
METHODS
TRIAL DESIGN AND PATIENTS. Details of the
CIBIS-ELD trial design have been published
previously (16). This investigator-initiated, random-
ized, double-blind, double-dummy, parallel group
trial was performed in Germany, Montenegro, Serbia,
and Slovenia. Patients eligible for inclusion were
adults 65 years or older with symptomatic chronic HF
consistent with NYHA functional class $II at presen-
tation and either a reduced LVEF #45% (HFrEF pa-
tients) or a preserved ejection fraction (LVEF >45%)
(HFpEF patients), with evidence of diastolic dysfunc-
tion as deﬁned below. At baseline, eligible participants
had to be BB naïve or currently taking #25% of the
recommended BB dose for HFrEF (#2.5 mg once daily
for bisoprolol; #6.25 mg twice daily for carvedilol).
They had to be clinically stable with no changes in HF
medication for at least 2 weeks before randomization.
Major exclusion criteria were known contraindications
to BB treatment such as hypotension with a resting
systolic BP < 90 mm Hg, severe pulmonary disease or
severe asthma, bradycardia with a resting HR < 55
beats/min before commencement of therapy, second
or third degree sinoatrial block (without pacemaker)
and known sick sinus syndrome.
This is a pre-speciﬁed subgroup analysis of the
differences between HFpEF and HFrEF in the CIBIS-
ELD trial, which tested whether the target dose
could be reached more often with bisoprolol than
with carvedilol (14,16). Tolerability and clinical
effectiveness of bisoprolol versus that of carvedilol
on the burden of symptoms, functional capacity, and
echocardiographic assessment of systolic and dia-
stolic myocardial function in elderly HFrEF and
HFpEF patients were compared. Tolerability was
deﬁned as tolerance (yes/no) of the study medication
target dose as per cardiology guidelines recom-
mended (primary endpoint). Further endpoints were
time to treatment failure, % of target dose for long
term treatment, number of adverse events or serious
adverse events (14,16).
TABLE 1 Baseline Characteristics
All patients
(N ¼ 876)
HFpEF
(N ¼ 250)
HFrEF
(N ¼ 626) p Value
Age, yrs 72.8  5.5 73.4  6.0 72.6  5.3 0.06
Women (%) 329 (38) 164 (66) 165 (26) <0.001
NYHA functional classes shown (%) 0.02
I 34 (4) 2 (1) 32 (5)
II 575 (66) 191 (76) 384 (61)
III 258 (30) 57 (23) 201 (32)
IV 9 (1) 0 (0) 9 (1)
Peripheral edema (%) 183 (21) 88 (35) 95 (15) <0.001
Heart rate on ECG, beats/min 73.5  14.3 70.7  12.8 74.6  14.8 <0.001
Blood pressure, mm Hg
Systolic 137.1  21.5 146.2  23.6 133.5  19.4 <0.001
Diastolic 80.0  11.8 80.4  12.5 79.8  11.5 0.49
Body mass index, kg/m2 27.7  4.9 29.5  5.9 27.1  4.2 <0.001
Left ventricular ejection fraction (%) 41.7  13.6 58.9  8.8 34.8  7.9 NA
NT-proBNP, pg/ml 609 (255–1,614) 253 (161–529) 968 (409–2,091) <0.001
Time since ﬁrst diagnosis of heart failure, yrs <0.001
<1 197 (23) 114 (46) 83 (13)
1-5 305 (35) 69 (28) 236 (38)
>5 248 (28) 25 (10) 223 (36)
Unknown 126 (14) 42 (17) 84 (13)
Primary cause of heart failure <0.001
CAD 455 (52) 79 (32) 376 (60)
DCM 123 (14) 4 (2) 119 (19)
Hypertension 223 (25) 140 (56) 83 (13)
Other 75 (9) 27 (11) 48 (8)
No. of hospitalizations for heart failure
during the past 12 months (%)
314 (36) 51 (20) 263 (42) <0.001
No. with medical history shown (%)
Current smoker 76 (9) 19 (8) 57 (9) 0.51
Myocardial infarction 347 (40) 44 (18) 303 (48) <0.001
PCI and/or CABG 196 (22) 42 (17) 154 (25) 0.01
Pacemaker and/or ICD 56 (6) 7 (3) 49 (9) 0.005
Continued on the next page
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142The protocol and amendments were approved by
all responsible national institutes for drugs and
medical devices, as well as by national and local ethics
committees. All patients provided written informed
consent before enrolment, and all procedures related
to the trial conformed to the principles outlined in
the Declaration of Helsinki. CIBIS-ELD is registered
at www.controlled-trials.com under the identiﬁer
ISRCTN34827306.
STUDY MEDICATION. Patients were randomized to
either bisoprolol or carvedilol, independent of left
ventricular function. All patients, investigators, and
study personnel were blinded to treatment assign-
ment. According to the titration scheme for HFrEF
(on the basis of 2005 European Society of Cardiol-
ogy guidelines), the blinded treatment was titrated
to target doses over 10 weeks by doubling the dose
every 2 weeks (17). Thus, with a starting dose of
2.5 mg of bisoprolol once daily or carvedilol, 6.25
mg twice daily, patients were scheduled to reachthe target dose of 10 mg of bisoprolol or 25 mg of
carvedilol twice daily within 6 weeks (or 50 mg
twice daily within 8 weeks for patients receiving
carvedilol with a body weight >85 kg). When clini-
cally indicated, investigators were allowed to delay
dose titration, reduce the dose or discontinue the
study treatment. The titration phase was followed
by a 4-week maintenance period. The ﬁnal visit
was conducted at 10 weeks (or 12 weeks for patients
weighing >85 kg). Delayed up-titration to the
target dose was any titration that did not follow
the titration scheme (i.e. an up-titration step
was postponed to the next visit, or the study
medication was even temporarily down-titrated),
but eventually, the target dose was reached after
3 months.
LABORATORY MEASUREMENTS. At baseline and
at 12 weeks, blood samples were taken in standard-
ized conditions by venous puncture after a 20-minute
supine resting period. All samples were immediately
TABLE 1 Continued
All patients
(N ¼ 876)
HFpEF
(N ¼ 250)
HFrEF
(N ¼ 626) p Value
Comorbidities
Hypertension 724 (83) 224 (90) 500 (80) 0.001
Coronary artery disease 510 (58) 82 (33) 428 (68) <0.001
Diabetes mellitus 223 (26) 57 (23) 166 (27) 0.27
Hyperlipidaemia 548 (63) 165 (66) 383 (61) 0.19
Peripheral vascular disease or stroke 121 (14) 30 (12) 91 (15) 0.39
Atrial ﬁbrillation 164 (19) 25 (10) 139 (22) <0.001
Chronic obstructive pulmonary disease 65 (7) 22 (9) 43 (7) 0.32
Renal dysfunction (GFR <60) 338 (39) 68 (27) 270 (43) <0.001
Anemia (male: Hb <13 g/dl; female: Hb <12 g/dl) 181 (21) 38 (15) 143 (23) 0.01
Occurrence of depression 73 (8) 35 (14) 38 (6)
In men 31 (6) 2 (2) 29 (6) 0.20
In women 42 (13) 33 (20) 9 (5) <0.001
Interaction sex  LV function 0.001
No. taking cardiovascular medications shown (%)
Beta-blocker use at enrolment <0.001
None 349 (40) 131 (52) 218 (35)
12.5% of target dose equivalent 149 (17) 24 (10) 125 (20)
25% of target dose equivalent 378 (43) 95 (38) 283 (45)
ACE inhibitor and/or ARB 741 (85) 190 (76) 551 (88) <0.001
Aldosterone receptor antagonist 275 (31) 21 (8) 254 (41) <0.001
Diuretic agent 649 (74) 146 (58) 503 (80) <0.001
Cardiac glycoside 129 (15) 17 (7) 112 (18) <0.001
Calcium channel blocker 143 (16) 62 (25) 81 (13) <0.001
Nitrate 277 (32) 32 (13) 245 (39) <0.001
Antiarrhythmic 95 (11) 5 (2) 90 (14) <0.001
Statin 342 (39) 77 (31) 265 (42) 0.002
Antiplatelet 582 (66) 122 (49) 460 (73) <0.001
Anticoagulant agent 220 (25) 37 (15) 183 (29) <0.001
Values are mean  SD, n (%), or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary artery disease; DCM¼ dilated cardiomyopathy; GFR ¼ glomerular ﬁltration rate;
HFpEF ¼ heart failure with preserved ejection fraction; HRrEF ¼ heart failure with reduced ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; LV ¼ left ventricle;
NA ¼ Non-applicable; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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143centrifuged and stored below 80C. N-terminal pro–
B-type natriuretic peptide (NT-proBNP) was analyzed
using a commercially available Elecsys proBNP
sandwich immunoassay on an Elecsys 2010 analyzer
(Roche Diagnostics, Berlin, Germany).
ECHOCARDIOGRAPHY. Echocardiography was per-
formed according to current guidelines of the Amer-
ican Society of Echocardiography, including
comprehensive evaluation of diastolic function with
Doppler and tissue Doppler techniques. All examina-
tions were performed by experienced echocardiog-
raphers who were blinded to treatment assignment.
LVMI and left atrial volume index (LAVI) were calcu-
lated as also recommended by the American Society of
Echocardiography (18).
Diastolic function in CIBIS-ELD was evaluated
and graded according to a standardized protocol
developed by the nationwide German Competence
Network Heart Failure (19,20).STATISTICAL ANALYSIS. Baseline characteristics of
HFpEF and HFrEF patients were compared by using
the t test for quantities, by Kendall’s tau for ordinal
variables, and by Fisher exact test for frequencies.
Changes in quantitative measurements from baseline
to 12 weeks were assessed within each of the groups
by t tests for paired variables, and were compared
between groups by analysis of covariance with the 12
weeks value as dependent variable, the baseline
value as covariate, and ventricular function as the
group variable. Correlations of changes in functional
variables and quality of life (QoL) were described by
Kendall’s tau for each of the functional groups sepa-
rately, and the tau coefﬁcients were compared be-
tween groups using the Gauss approximation test.
Analyses were performed using SPSS version 15 soft-
ware (SPSS Inc., Chicago, Illinois).
FUNDING AND RESPONSIBILITIES. The project was
initiated and coordinated by investigators of the
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144Competence Network Heart Failure (Project Multi-
center Trials), a group of investigators funded by the
German Federal Ministry of Education and Research
(19). The sponsor of the trial according to ICH-GCP
was the Charité University Hospital in Berlin, Ger-
many. Merck KGaA supported the trial with an unre-
stricted research grant without any rights to inﬂuence
trial design, data collection, data analysis, and inter-
pretation or publication of the results and thus did
not interfere with the investigators’ intellectual
property rights. The senior biometrician and the cor-
responding author had full access to all data. The ﬁrst
and corresponding authors had ﬁnal responsibility for
the decision to submit the paper for publication.
RESULTS
PATIENTS. Of 883 CIBIS-ELD patients, 876 patients
(mean age: 72.8  5.5, 38% female; mean LVEF
58.7  8.8% in HFpEF, 34.9  8.0% in HFrEF)
received bisoprolol or carvedilol and were available
for analysis. HFpEF was diagnosed in 250 patients
(29%) and HFrEF in 626 patients (71%). In the HFrEF
group, 317 patients (51%) received carvedilol, and
309 (49%) received bisoprolol. In the HFpEF group,
127 patients (51%) received carvedilol and 123 (49%)
bisoprolol. Baseline characteristics are shown in
Table 1. HFpEF patients were more frequently fe-
male and tended to be older, with greater body mass
index (BMI), higher systolic BP and lower resting
HRs at baseline, in lower NYHA functional classes,
with more peripheral edema and lower NT-proBNP
levels. More HFpEF patients were BB-naïve (52%
vs. 35% in HFrEF) and had lower rates of coronary
artery disease.
TOLERABILITY TO TARGET DOSE AND MEAN DAILY
BB DOSE. At the end of the titration period 31% (n ¼
77) of HFpEF patients and 31% (n ¼ 197) in HFrEF had
reached the target dose (between group comparison
p ¼ 0.87), as presented on Figure 1. Among these pa-
tients, 62% of HFpEF patients (n ¼ 48) reached the
target dose as scheduled versus 84% of HFrEF pa-
tients (n ¼ 166; HFpEF vs. HFrEF; p < 0.01). For both
bisoprolol and carvedilol, delayed up-titration was
observed more frequently in HFpEF patients than in
HFrEF patients (bisoprolol, p ¼ 0.001; carvedilol,
p ¼ 0.04); however, no signiﬁcant differences were
observed in mean daily doses following titration
(bisoprolol: 4.93  3.70 mg for HFrEF vs. 5.01  3.61
mg for HFpEF; p ¼ 0.83; whereas carvedilol: 29.1 
25.9 mg for HFrEF vs. 25.3  18.6 mg HFpEF;
p ¼ 0.09). Of the total number of patients, 7% (n ¼ 60)
had a delay in up-titration to the target dose: 31 (5%)
in HFrEF and 29 (12%) in HFpEF.Forty-eight HFpEF patients (19%) vs. 166 HFrEF
patients (27%) reached the primary endpoint of the
CIBIS-ELD trial (deﬁned as reaching the target dose
through biweekly dose doubling with no more than 1
delayed titration step and with the target dose main-
tained for at least 10 days; p ¼ 0.02). Fewer HFpEF
patients reached the target dose than HFrEF patients,
regardless of the treatment group (bisoprolol: 81, 26%
vs. 21, 17%, carvedilol 85, 27% vs. 27, 21%; p ¼ 0.52 for
homogeneity of differences, p ¼ 0.02 for agent-
adjusted difference between HFpEF and HFrEF).
When we adjusted for age, BMI, and NYHA functional
class, this result remained the same, although the
odds ratio (OR) of HFpEF versus HFrEF for reaching
the primary endpoint (OR: 0.66; 95% conﬁdence in-
terval [CI]: 0.46 to 0.95; p ¼ 0.02) became nonsigniﬁ-
cant (OR: 0.79; 95% CI: 0.54 to 1.14, p ¼ 0.21) when
adjusting for baseline HR and BB pre-treatment.
More HFpEF patients experienced adverse events
(79% vs. 58%, respectively, p < 0.001), regardless of
agent. Bradycardia (51 [20%] vs. 66 [11%], respec-
tively), dizziness (37 [15%] vs. 28 [4%]) and fatigue
(44 [18%] vs. 25 [4%]) occurred more frequently in
HFpEF patients (all p < 0.001). Differences remained
signiﬁcant even when we adjusted for baseline HR,
BB pre-treatment, age, BMI, and NYHA functional
class (p < 0.001).
CLINICAL EFFECTS, FUNCTIONAL STATUS, AND
QoL. There were no signiﬁcant differences between
bisoprolol and carvedilol with regard to clinical pa-
rameters in either group. Although the reduction of
HR was signiﬁcantly higher with bisoprolol, the
overall reductions of HR and diastolic BPs were
comparable in HFrEF and HFpEF (drug by ventricular
function interaction: p ¼ 0.71, adjusted for BB pre-
treatment). However, systolic BP reduction was
more marked in HFpEF patients (Table 2). NYHA
functional class improved to a lesser extent in HFpEF
patients than in HFrEF patients. There was a signiﬁ-
cant increase in NT-proBNP in HFpEF patients,
whereas NT-proBNP remained stable in HFrEF.
Scores for 6-minute-walk distances and physical
QoL improved in the HFrEF group. In HFpEF patients,
the reduction of HR was not associated with changes
in subjectively or objectively measured parameters of
physical and myocardial function (Tables 2 and 3). In
HFrEF, HR reduction was associated with improve-
ments in NYHA functional class, self-reported phys-
ical functioning (SF-36 PFS), and LVEF (all p < 0.05).
Reduction of BP was not related to changes in QoL or
functional status in either group.
CHANGES IN SYSTOLIC AND DIASTOLIC FUNCTION.
LVEF and left ventricular end-diastolic diameter
FIGURE 1 Percentage of HFrEF and HFpEF Patients Reaching the Targeted
Beta-Blocker Dose by the End of the 12-Week Titration Period
HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced
ejection fraction.
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145(LVEDD) and left ventricle end-systolic diameter
(LVESD) improved in HFrEF patients but not in
HFpEF patients (Table 3). There were no changes in
key parameters of diastolic function (E/e’) or atrial
remodelling (LAVI) in either group; however, an in-
crease in E/A mitral ﬂow ratio was observed in HFpEF
patients only (baseline: EA 0.84  0.32; at 12 weeks,
E/A was 0.91  0.36; p < 0.001). There were no dif-
ferences between bisoprolol and carvedilol in regard
to echocardiographic parameters.
DISCUSSION
This pre-speciﬁed subgroup analysis of the CIBIS-ELD
trial is the ﬁrst detailed comparison between of 2
commonly used BBs with distinct pharmacological
proﬁles in elderly HFrEF versus HFpEF patients, and
therefore gives valuable information about the use of
BB in HFpEF, namely, BB titration was more difﬁcult
in HFpEF patients than in HFrEF patents and led to
more titration delays and side effects. Only 19% of
HFpEF patients versus 27% of HFrEF patients
reached the primary endpoint deﬁned as titration to
the target dose without delay, although in both
groups, 31% of the patients ﬁnally reached the target
dose. This implies that it might take more time to
titrate HFpEF patients on a BB dose than HFrEF pa-
tients. As there is no exact deﬁnition of “tolerability,”
one could discuss whether it is more important
to reach a target dose rather than reach it without
any delay.
We found no differences between the probabilities
of HFpEF and HFrEF patients reaching the target
dose, but HFpEF patients experienced more titration
delays and more adverse events.
Both BBs were comparable regarding their tolera-
bility and clinical effectiveness in HFrEF and HFpEF.
Reduction of HR and BP was greater in HFpEF pa-
tients than in HFrEF patients, which is in concor-
dance with previously published results (21). This
ﬁnding therefore further supports the evidence
regarding the substantial hemodynamic differences
between HFpEF and HFrEF. Despite the signiﬁcant
reduction in HR and BP at 12 weeks, there was modest
improvement in NYHA functional class, although self-
reported physical functioning, 6-minute-walk dis-
tance, and echocardiographic parameters of systolic
and diastolic functions did not improve in HFpEF,
unlike those in HFrEF patients. We could not show a
clear clinical beneﬁt in the HFpEF group (except for
the previously mentioned slight improvement in
NYHA functional class, after BB titration), although
the limitation of this trial was that we did not have a
placebo group. It is also important to mention thatthere was a signiﬁcant improvement in QoL in all
subscales in HFrEF patients but not in those in HFpEF
patients.
PATIENTS. Although several small studies, registry
data and post-hoc analyses of the SENIOR study seem
to support the use of BBs in HFpEF, results regarding
the clinical effectiveness of BBs in HFpEF patients
remain inconsistent and tolerability was addressed
only once previously (6,9). Differences in methodol-
ogy, HFpEF deﬁnition and sample composition limit
the comparability of previous studies. In our analysis
the diagnosis of HFpEF was on the basis of HF signs
and symptoms and on the absence of a reduced LVEF
using a prognostically relevant cut-off value of 45%
(22). Furthermore, as required by the current ESC
and AHA/ACC guidelines, echocardiographic evi-
dence of diastolic dysfunction was required for all
HFpEF patients (20). In previous large trials investi-
gating HFpEF, the presence of diastolic dysfunction
as determined by echocardiography was often not
required for study eligibility; treatment-related ef-
fects on diastolic function were often investigated in
subgroups only (4). Stringent diagnostic criteria for
HFpEF are essential to avoid the inclusion of falsely
diagnosed patients in clinical trials, especially as
common co-morbidities may mimic the HFpEF
symptoms. Inhomogeneous HFpEF deﬁnition and
differences in phenotyping may account for the fail-
ure of large trials. Our deﬁnition made possible to
include HFpEF patients with typical clinical and
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146demographic characteristics. As shown in previous
community-based and interventional studies, HFpEF
patients in this study were in lower NYHA functional
classes, less severely affected in QoL dimensions and
less frequently treated with cardiovascular drugs
(2,3,9). Furthermore, they demonstrated low rates of
coronary artery disease, which has been proposed as
an indicator of sample quality (23).
TOLERABILITY OF THE TARGET DOSE AND MEAN
DOSE. After adjusting for baseline HR and BB pre-
treatment, HFpEF patients achieved the primary
tolerability endpoint of the CIBIS-ELD trial as often as
HFrEF patients regardless of the BB used. In general,
only 19% versus 27% fulﬁlled these criteria in both
groups, which is markedly lower than previously re-
ported for HFrEF (9). Similar mean daily doses for
bisoprolol and carvedilol were observed at the end of
titration in HFpEF and HFrEF patients. The SENIOR
study reported that 67% of HF patients reached theTABLE 2 Clinical Endpoints
Trea
HFpEF
(N ¼ 250)
Heart rate on ECG (beats/min)
Mean change (95% CI) –6.6 (–8.0 to 5.2)
p < 0.001
Blood pressure systolic ( mm Hg)
Mean change (95% CI) –14.3 (–17.7 to 11.0)
p < 0.001
Diastolic blood pressure (mm Hg)
Mean change (95% CI) –5.2 (–6.9 to 3.5)
p < 0.001
NYHA functional class
Mean change (95% CI) –0.18 (–0.25 to 0.11)
p < 0.001
6-min walk distance (m)
Mean change (95% CI) 4 (–8 to 16)
p ¼ 0.52
Log 10 NT-proBNP
Mean change (95% CI) 0.05 (0.00 to 0.10)
p ¼ 0.03
SF-36 PFS
Mean change (95% CI) 1.1 (1.7 to 3.9)
p ¼ 0.44
SF-36 PCS
Mean change (95% CI) 1.1 (0.1 to 2.2)
p ¼ 0.08
SF-36 MCS
Mean change (95% CI) 0.4 (1.2 to 2.0)
p ¼ 0.61
*Adjusted for beta-blocker pre-treatment and study drug.
ECG ¼ electrocardiography; NT-proBNP ¼ N-terminal pro b-type natriuretic peptide;
survey (SF-36) mental component su mmary score; SF-36 PCS ¼ short-form quality of lif
quality of life health survey (SF-36) physical functioning score; SRH ¼ self-rated healthmaximal dose of nebivolol after titration period.
Furthermore, they found no signiﬁcant differences
between HFrEF and HFpEF patients (24). The strin-
gent deﬁnition of tolerability in our trial (including a
time-to-target-dose criterion), the predominant in-
clusion of younger patients in former trials in HFrEF
and differences in pharmacological proﬁle of inves-
tigated BBs might be the most important contributors
to the high rate of failure to reach primary endpoint in
both HFpEF and HFrEF in our trial.
MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION. In
HFrEF patients there is strong evidence that BB
treatment results in LVEF improvement and has the
potential to reduce left ventricular volumes (25).
Similarly, we observed echocardiographic improve-
ment in HFrEF patients regardless on the substance
used. Not surprisingly, neither bisoprolol nor carve-
dilol had an effect on LVEF, LVEDD, or LVES in
HFpEF patients.tment Group Difference
HFrEF
(N ¼ 626) HFpEF vs. HFrEF*
6.9 (–8.0 to 5.7) 1.2 (–0.8 to 3.2)
p < 0.001 p ¼ 0.25
7.5 (–9.1 to 5.9) 6.4 (9.7 to 3.0)
p < 0.001 p < 0.001
4.1 (5.1 to 3.1) 0.7 (2.6 to 1.3)
p < 0.001 p ¼ 0.49
0.31 (0.35 to 0.26) 0.14 (0.05 to 0.23)
p < 0.001 p ¼ 0.002
20 (15 to 25) 15 (26 to 4)
p < 0.001 p ¼ 0.008
0.00 (0.04 to 0.03) 0.05 (0.01 to 0.11)
p ¼ 0.82 p ¼ 0.13
4.9 (2.9 to 6.9) 4.3 (8.2 to 0.4)
p < 0.001 p ¼ 0.03
2.5 (1.8 to 3.3) 1.7 (3.2 to 0.2)
p < 0.001 p ¼ 0.02
3.8 (2.9 to 4.7) p < 0.001
p < 0.001
NYHA ¼ New York Heart Association; SF-36 MCS ¼ short-form quality of life health
e health survey (SF-36) physical component summary score; SF-36 PFS ¼ short-form
score.
TABLE 3 Echocardiographically Determined Left Ventricular Dimensions and Myocardial Function
Treatment Group Difference
HFpEF
(N ¼ 250)
HFrEF
(N ¼ 626) HFpEF vs. HFrEF
LVEF (%)
Baseline, mean  SD 58.7  8.8 34.9  8.0
12 weeks, mean  SD 59.0  8.3 38.8  9.1
Mean change (95% CI) 0.4 (0.6 to 1.4) 3.8 (3.3 to 4.4) 3.5 (4.6 to 2.3)
p ¼ 0.47 p < 0.001 p < 0.001
LVEDD (mm)
Baseline, mean  SD 47.6  7.5 60.3  9.5
12 weeks, mean  SD 47.9  6.4 59.8  8.7
Mean change (95% CI) 0.2 (0.5 to 0.9) 0.5 (0.9 to 0.1) 0.6 (0.1 to 1.4)
p ¼ 0.52 p ¼ 0.01 p ¼ 0.11
LVESD (mm)
Baseline, mean  SD 31.1  7.1 47.8  10.0
12 weeks, mean  SD 31.4  6.4 46.4  9.8 1.7 (0.8 to 2.5)
Mean change (95% CI) 0.3 (0.5 to 1.1) 1.4 (1.8 to 0.9) p < 0.001
p ¼ 0.46 p < 0.001
E/e0
Baseline, mean  SD 11.0  5.6 12.2  9.3
12 weeks, mean  SD 10.7  5.2 11.9  9.6
Mean change (95% CI) 0.3 (0.9 to 0.3) 0.3 (1.0 to 1.4) 0.0 (1.2 to 1.1)
p ¼ 0.29 p ¼ 0.38 p ¼ 0.95
E/A
Baseline, mean  SD 0.84  0.32 1.13  0.91
12 weeks, mean  SD 0.91  0.36 1.15  0.87
Mean change (95% CI) 0.07 (0.03 to 0.11) 0.01 (0.05 to 0.08) 0.04 (0.07 to 0.15)
p ¼ 0.001 p ¼ 0.68 p ¼ 0.44
DT (ms)
Baseline, mean  SD 219  75 219  83
12 weeks, mean  SD 217  66 222  79
Mean change (95% CI) –2 (11 to 8) 4 (3 to 10) 6 (18 to 5)
p ¼ 0.74 p ¼ 0.27 p ¼ 0.29
IVRT (ms)
Baseline, mean  SD 97.1  27.6 114.1  35.3
12 weeks, mean  SD 102.6  32.6 114.0  32.7
Mean change (95% CI) 5.6 (0.6 to 10.5) 0.1 (3.2 to 3.0) 4.0 (1.8 to 9.7)
p ¼ 0.03 p < 0.94 p ¼ 0.18
LAVI (ml/m2)
Baseline, mean  SD 28.0  10.9 36.0  14.4
12 weeks, mean  SD 28.6  10.8 35.7  14.3
Mean change (95% CI) 0.6 (0.4 to 1.6) 0.2 (0.9 to 0.5) 0.8 (0.4 to 2.1)
p ¼ 0.24 p ¼ 0.53 p ¼ 0.20
DD grade
Baseline, mean  SD 1.22  0.55 1.61  0.75
12 weeks, mean  SD 1.18  0.57 1.58  0.75
Mean change (95% CI) 0.04 (0.10 to 0.03) 0.02 (0.08 to 0.03) 0.02 (0.11 to 30.8)
p ¼ 0.28 p ¼ 0.36 p ¼ 0.74
DD ¼ diastolic dysfunction; DT ¼ deceleration time; E/e0 ¼ E/e0 ratio; EA ¼ E/A ratio; IVRT ¼ isovolumic relaxation time; LAVI ¼ left atrial volume index; LVEDD ¼ left
ventricular end-diastolic diameter; LVESD ¼ left ventricle end-systolic diameter.
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147The severity of diastolic dysfunction is related to
the functional capacity of HFpEF patients (26); thus
an improvement of these properties is considered an
appropriate target. Impaired relaxation and diastolic
left ventricular ﬁlling, which are pathophysiologicalhallmarks of HFpEF (15), did not improve signiﬁcantly
over the 12-week titration period. The short obser-
vation period may account for the lack of diastolic
improvement, however as reported previously in
small trial of carvedilol in HFpEF with a 6-month
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
most elderly patients with HFpEF, an algorithm-based
up-titration of BB to a given target dose is not
feasible. Our results suggest that BB titration in
HFpEF patients is safe but that it should be carried out
with caution because of adverse events and more
delays in reaching an appropriate dose. These results,
therefore, are of importance for the growing propor-
tion of HFpEF patients within the HF population who
are already taking BB for the treatment of
comorbidities.
TRANSLATIONAL OUTLOOK: A large, prospec-
tive, randomized outcome trial is now urgently
needed to deﬁne the role of BB in HFpEF.
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148follow-up period we found a modest improvement in
the E/A mitral inﬂow ratio (6).
CLINICAL EFFECTS: FUNCTIONAL CAPACITY, QoL,
AND NT-proBNP. Despite greater reductions in BP
and a similar reduction of HR at 12 weeks, HFpEF
patients demonstrated no corresponding improve-
ments in self-reported physical functioning, QoL or
6-minute-walk-distance. Of particular interest, NT-
proBNP levels in HFpEF increased over this time
period.
Although rate-lowering drugs are thought to
improve left ventricular ﬁlling by lengthening the
diastolic period thus increasing stroke volume and
cardiac output, exercise intolerance was found to be
more frequent in HFpEF patients treated with BBs
in a recent study, possibly due to their negative
inotropic properties (27,28). These ﬁndings are in
concordance with the ELANDD trial, which show
worsened exercise capacity in HFpEF patients
treated with nebivolol (28). For this and other rea-
sons the If-channel inhibitor ivabradine, which does
not affect cardiac inotropy, has been studied in
HFpEF. Recent small, placebo-controlled trials of
ivabradine have shown improvements in exercise
capacity and echocardiographic measures of dia-
stolic dysfunction at rest (DT, E/E0 ratio, IVRT) and
during exercise (E/A ratio) (29). However, despite
no effect on E/E0 or LAVI in our study, NT-proBNP
increased in HFpEF after BB titration, which rather
indicates a worsening of left ventricular ﬁlling
pressure.
Also the presence of the BB-related induction of
chronotropic incompetence (CTI) is known to be a
major contributor to exercise intolerance in this
condition, might have inﬂuenced our results. CTI af-
fects 25% to 30% of all HFpEF patients according to
certain studies (27,30), whereas others show that the
prevalence can be as high as 57% (31). Autonomic
dysfunction is a main contributing factor to CTI (32),
which is more common in patients receiving BBs (32).
However, CTI was not investigated in our trial,
wherefore only assumptions on the potential impact
of CTI can be made.
STUDY LIMITATIONS. The intention of this trial was
the comparison of bisoprolol versus carvedilol and
therefore there was no placebo group and all the
mentioned statements regarding changes from
baseline, should be interpreted with caution.
Because of the main target of this study to investi-
gate tolerability of BB titration, only well compen-
sated patients were enrolled and results should not
be extrapolated towards more advanced HF.
Although all echocardiographers were blinded totreatment allocation of the patients, the absence of
an echocardiography core lab could potentially
interact with the results.
Compared to HFrEF patients, we found no effects
on relevant clinical or functional parameters in the
HFpEF group. However, studies that would explore
the effects of BB on these secondary parameters,
would need to be powered for NT-proBNP or E/e’ as
primary endpoints.
For all the reasons mentioned above, a larger
controlled trial with longer treatment and follow-up
periods is urgently needed to gather more evidence
about the value or harmfulness of BB treatment in
HFpEF.
CONCLUSIONS
Even though there were numerous differences in
clinical response between elderly HFpEF and HFrEF
patients, overall tolerability of BBs as deﬁned by our
protocol, was low, both in HFpEF and HFrEF. Despite
BB titration in HFpEF and HFrEF was feasible and
safe, titration delays and none severe side effects
more often occurred in HFpEF. Nevertheless the need
for a bigger outcome trial which would address the
question of clinical effectiveness in terms of mortality
reduction is evident.
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